Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 38, Issue 3, 2001, Pages 171-175

  Markman, Maurie ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Carboplatin; Cisplatin; Intraperitoneal chemotherapy; Ovarian cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS;

EID: 0035022919     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00097-X     Document Type: Review

References (30)

1. Markman M. Intraperitoneal chemotherapy. Crit. Rev. Oncol. Hematol. 31:1999;239-246.
2. Dedrick R.L., Myers C.E., Bungay P.M., et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62:1978;1-9.
3. Dedrick R.L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin. Oncol. 12:(3, suppl 4):1985;1-6.
4. Alberts D.S., Young L., Mason N., et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin. Oncol. 12:(3, Suppl 4):1985;38-42.
5. Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit. Rev. Oncol. Hematol. 14:1993;15-28.
6. Howell S.B., Pfeifle C.E., Wung W.E., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97:1982;845-851.
7. Casper E.S., Kelsen D.P., Alcock N.W., et al. Ip cisplatin in patients with malignant ascites: pharmacokinetics evaluation and comparison with the iv route. Cancer Treat. Rep. 67:1983;325-338.
8. Lopez J.A., Krikorian J.G., Reich S.D., et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol. Oncol. 20:1985;1-9.
9. Pretorius R.G., Hacker N.F., Berek J.S., et al. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat. Rep. 67:1983;1085-1092.
10. Markman M., Reichman B., Hakes T., et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J. Clin. Oncol. 9:1991;1801-1805.
11. Markman M., Berek J.S., Blessing J.A., et al. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: lessons learned from a gynecologic oncology group phase II trial of IP cisplatin and recombinant alpha-interferon. Gynecol. Oncol. 45:1992;3-8.
12. Markman M., Blessing J.A., Major F., et al. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a gynecologic oncology group study. Gynecol. Oncol. 50:1993;191-195.
13. Berek J.S., Welander C., Schink J.C., Grossberg H., Montz F.J., Zigelboim J. A phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with persistent epithelial ovarian cancer. Gynecol. Oncol. 40:1991;237-243.
14. Morgan R.J., Braly P., Leong L., et al. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. Gynecol. Oncol. 77:2000;433-438.
15. Feun L.G., Blessing J.A., Major F.J., DiSaia P.J., Alvarez R.D., Berek J.S. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a gynecologic oncology group study. Gynecol. Oncol. 71:1998;410-415.
16. Recio F.O., Piver M.S., Hempling R.E., Driscoll D.L. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol. Oncol. 68:1998;267-273.
17. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335:1996;1950-1955.
18. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group, J. Clin. Oncol., 2001;19:1001-7.
19. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
20. Shapiro F., Schneider J., Markman M., et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol. Oncol. 67:1997;39-45.
21. Markman M., Rowinsky E., Hakes T., et al. Phase 1 trial of intraperitoneal taxol: a gynecologic oncology group study. J. Clin. Oncol. 10:1992;1485-1491.
22. Francis P., Rowinsky E., Schneider J., et al. Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J. Clin. Oncol. 13:1995;2961-2967.
23. Markman M., Brady M.F., Spirtos N.M., et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a gynecologic oncology group study. J. Clin. Oncol. 16:1998;2620-2624.
24. Los G., Mutsaers P.H.A., van der Vijgh W.J.F., Baldew G.S., de Graaf P.W., McVie J.G. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 49:1989;3380-3384.
25. Los G., Mutsaers P.H.A., Lenglet W.J.M., Baldew G.S., McVie J.G. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother. Pharmacol. 25:1990;389-394.
26. Los G., Verdegaal E.M.E., Mutsaers P.H.A., McVie J.G. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 28:1991;159-165.
27. Markman M., Reichman B., Hakes T., et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small volume residual ovarian cancer. Gynecol. Oncol. 50:1993;100-104.
28. Speyer J.L., Beller U., Colombo N., et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J. Clin. Oncol. 8:1990;1335-1341.
29. Pfeiffer P., Bennedbaek O., Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol. Oncol. 36:1990;306-311.
30. Elferink F., van der Vijgh W.J.F., Klein I., ten Bokkel Huinink W.W., Dubbelman R., McVie J.G. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol. 21:1988;57-60.